Merck & Co. Inc (MRK) is a leading drug manufacturers-general business based in the US. It opened the day at USD$79.32 after a previous close of USD$79.49. During the day the price has varied from a low of USD$79.31 to a high of USD$81.25. The latest price was USD$81.07 (25 minute delay). Merck is listed on the NYSE and employs 73,000 staff. All prices are listed in US Dollars.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Since the stock market crash in March caused by coronavirus, Merck's stock price has had significant negative movement.
Its last market close was $81.07, which is 1.54% down on its pre-crash value of $82.34 and 24.25% up on the lowest point reached during the March crash when the stocks fell as low as $65.25.
If you had bought $1,000 worth of Merck stocks at the start of February 2020, those stocks would have been worth $760.28 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $928.25.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|52-week range||$66.61 - $84.56|
|50-day moving average||$76.05|
|200-day moving average||$75.59|
|Wall St. target price||$94.08|
|Dividend yield||$2.52 (3.22%)|
|Earnings per share (TTM)||$2.20|
|1 week (2021-10-14)||3.50%|
|1 month (2021-09-21)||12.64%|
|3 months (2021-07-21)||6.13%|
|6 months (2021-04-21)||2.32%|
|1 year (2020-10-21)||3.92%|
|2 years (2019-10-21)||-4.01%|
|3 years (2018-10-19)||12.14%|
|5 years (2016-10-21)||32.57%|
Valuing Merck stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merck's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Merck's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 36x. In other words, Merck shares trade at around 36x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Merck's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4275. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merck's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Merck's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $19.9 billion.
The EBITDA is a measure of a Merck's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$50.4 billion|
|Operating margin TTM||33.02%|
|Gross profit TTM||$34.6 billion|
|Return on assets TTM||11.47%|
|Return on equity TTM||20.4%|
|Market capitalisation||$198.3 billion|
TTM: trailing 12 months
There are currently 22.6 million Merck shares held short by investors – that's known as Merck's "short interest". This figure is 17.7% down from 27.4 million last month.
There are a few different ways that this level of interest in shorting Merck shares can be evaluated.
Merck's "short interest ratio" (SIR) is the quantity of Merck shares currently shorted divided by the average quantity of Merck shares traded daily (recently around 13.2 million). Merck's SIR currently stands at 1.71. In other words for every 100,000 Merck shares traded daily on the market, roughly 1710 shares are currently held short.
However Merck's short interest can also be evaluated against the total number of Merck shares, or, against the total number of tradable Merck shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Merck's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Merck shares in existence, roughly 10 shares are currently held short) or 0.009% of the tradable shares (for every 100,000 tradable Merck shares, roughly 9 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Merck.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Merck.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 28.35
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Merck's overall score of 28.35 (as at 12/31/2018) is nothing to write home about – landing it in it in the 47th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Merck is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.15/100
Merck's environmental score of 3.15 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 15.55/100
Merck's social score of 15.55 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 12.65/100
Merck's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Merck is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Merck scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Merck hasn't always managed to keep its nose clean.
Dividend payout ratio: 44.01% of net profits
Recently Merck has paid out, on average, around 44.01% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.32% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Merck shareholders could enjoy a 3.32% return on their shares, in the form of dividend payments. In Merck's case, that would currently equate to about $2.52 per share.
While Merck's payout ratio might seem fairly standard, it's worth remembering that Merck may be investing much of the rest of its net profits in future growth.
Merck's most recent dividend payout was on 6 October 2021. The latest dividend was paid out to all shareholders who bought their shares by 13 September 2021 (the "ex-dividend date").
Merck's shares were split on a 1048:1000 basis on 2 June 2021. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1048 shares. This wouldn't directly have changed the overall worth of your Merck shares – just the quantity. However, indirectly, the new 4.6% lower share price could have impacted the market appetite for Merck shares which in turn could have impacted Merck's share price.
Over the last 12 months, Merck's shares have ranged in value from as little as $66.6082 up to $84.56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Merck's is 0.4169. This would suggest that Merck's shares are less volatile than average (for this exchange).
Merck & Co. , Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co.
Steps to owning and managing Bucket Studio shares from South Africa.
Learn how to stake AVAX tokens and earn rewards by supporting the Avalanche blockchain.
True to its name, SuperRare is an NFT marketplace that focuses on crypto art tokenised on the Ethereum blockchain. The result is part marketplace and part social network for the artistic side of the NFT community.
Steps to owning and managing Evergrande shares from South Africa.
This guide will show you step-by-step instructions on how to buy the Bitcoin Gold (BTG) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the DexTools (DEXT) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the SOLVE (SOLVE) token as well as a list of exchanges you can trade it on.
Buy and sell unique digital assets on the largest NFT marketplace in the crypto space.
An all-encompassing guide on NFT marketplaces. Learn how to sell, buy and create your own NFTs on the world’s most popular marketplaces.
This guide will show you step-by-step instructions on how to buy the Smooth Love Potion (SLP) token as well as a list of exchanges you can trade it on.
finder.com.au is one of Australia's leading comparison websites. We compare from a wide set of banks, insurers and product issuers. We value our editorial independence and follow editorial guidelines.
finder has access to track details from the product issuers listed on our sites. Although we provide information on the products offered by a wide range of issuers, we don't cover every available product or service.
Please note that the information published on our site should not be construed as personal advice and does not consider your personal needs and circumstances. While our site will provide you with factual information and general advice to help you make better decisions, it isn't a substitute for professional advice. You should consider whether the products or services featured on our site are appropriate for your needs. If you're unsure about anything, seek professional advice before you apply for any product or commit to any plan.
Products marked as 'Promoted' or 'Advertisement' are prominently displayed either as a result of a commercial advertising arrangement or to highlight a particular product, provider or feature. Finder may receive remuneration from the Provider if you click on the related link, purchase or enquire about the product. Finder's decision to show a 'promoted' product is neither a recommendation that the product is appropriate for you nor an indication that the product is the best in its category. We encourage you to use the tools and information we provide to compare your options.
Where our site links to particular products or displays 'Go to site' buttons, we may receive a commission, referral fee or payment when you click on those buttons or apply for a product.
When products are grouped in a table or list, the order in which they are initially sorted may be influenced by a range of factors including price, fees and discounts; commercial partnerships; product features; and brand popularity. We provide tools so you can sort and filter these lists to highlight features that matter to you.
We try to take an open and transparent approach and provide a broad-based comparison service. However, you should be aware that while we are an independently owned service, our comparison service does not include all providers or all products available in the market.
Some product issuers may provide products or offer services through multiple brands, associated companies or different labelling arrangements. This can make it difficult for consumers to compare alternatives or identify the companies behind the products. However, we aim to provide information to enable consumers to understand these issues.
Providing or obtaining an estimated insurance quote through us does not guarantee you can get the insurance. Acceptance by insurance companies is based on things like occupation, health and lifestyle. By providing you with the ability to apply for a credit card or loan, we are not guaranteeing that your application will be approved. Your application for credit products is subject to the Provider's terms and conditions as well as their application and lending criteria.